Alaunos Therapeutics Investor Relations Material

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company, which develops adoptive TCR engineered T-cell therapies. The company is developing ALNS-1VJ001, a CD19 targeted adoptive cell therapy, to treat B-cell malignancies and lymphomas. Its lead product candidate ALNS-1VJ001 is undergoing clinical trials as a combination therapy with bendamustine hydrochloride (Treanda) for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Alaunos Therapeutics, Inc. has strategic alliance with Merck & Co., Inc.